Lanreotide

Revision as of 16:46, 9 August 2012 by WikiBot (talk | contribs) (Robot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +))
Jump to navigation Jump to search


Lanreotide
Clinical data
[[Regulation of therapeutic goods |Template:Engvar data]]
Pregnancy
category
  • AU: C
  • US: C (Risk not ruled out)
Routes of
administration
Intramuscular, subcutaneous
ATC code
Legal status
Legal status
Pharmacokinetic data
BioavailabilityApproximately 80%[1]
Protein binding78%[1]
MetabolismIn GI tract
Elimination half-life2 hours (immediate release)
5 days (sustained release)
ExcretionMostly biliary
Identifiers
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC54H69N11O10S2
Molar mass1096.33 g/mol
1156.380 g/mol (acetate)

WikiDoc Resources for Lanreotide

Articles

Most recent articles on Lanreotide

Most cited articles on Lanreotide

Review articles on Lanreotide

Articles on Lanreotide in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Lanreotide

Images of Lanreotide

Photos of Lanreotide

Podcasts & MP3s on Lanreotide

Videos on Lanreotide

Evidence Based Medicine

Cochrane Collaboration on Lanreotide

Bandolier on Lanreotide

TRIP on Lanreotide

Clinical Trials

Ongoing Trials on Lanreotide at Clinical Trials.gov

Trial results on Lanreotide

Clinical Trials on Lanreotide at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Lanreotide

NICE Guidance on Lanreotide

NHS PRODIGY Guidance

FDA on Lanreotide

CDC on Lanreotide

Books

Books on Lanreotide

News

Lanreotide in the news

Be alerted to news on Lanreotide

News trends on Lanreotide

Commentary

Blogs on Lanreotide

Definitions

Definitions of Lanreotide

Patient Resources / Community

Patient resources on Lanreotide

Discussion groups on Lanreotide

Patient Handouts on Lanreotide

Directions to Hospitals Treating Lanreotide

Risk calculators and risk factors for Lanreotide

Healthcare Provider Resources

Symptoms of Lanreotide

Causes & Risk Factors for Lanreotide

Diagnostic studies for Lanreotide

Treatment of Lanreotide

Continuing Medical Education (CME)

CME Programs on Lanreotide

International

Lanreotide en Espanol

Lanreotide en Francais

Business

Lanreotide in the Marketplace

Patents on Lanreotide

Experimental / Informatics

List of terms related to Lanreotide

Lanreotide (INN) is a medication used in the management of acromegaly and symptoms caused by neuroendocrine tumors, most notably carcinoid syndrome. It is a long-acting analogue of somatostatin, like octreotide.

Lanreotide (as lanreotide acetate) is manufactured by Ipsen, and marketed under the trade name Somatuline. It is available in several countries, including the United Kingdom, Australia and Canada, and was approved for sale in the United States by the Food and Drug Administration (FDA) on August 30 2007.[2]

Pharmacology

Lanreotide is a synthetic analogue of somatostatin, a naturally-occurring inhibitory hormone which blocks the release of several other hormones, including growth hormone, thyroid-stimulating hormone (TSH), insulin and glucagon. Lanreotide binds to the same receptors as somatostatin, although with higher affinity to peripheral receptors, and has similar activity. However, while somatostatin is quickly broken down in the body (within minutes),[3] lanreotide has a much longer half-life, and produces far more prolonged effects.

The efficacy of lanreotide has not been extensively studied, and results differ greatly between trials and formulations.

Indications

Lanreotide is used in the treatment of acromegaly, due to both pituitary and non-pituitary growth hormone-secreting tumors, and the management of symptoms caused by neuroendocrine tumors, particularly carcinoid tumors and VIPomas. In the United Kingdom, it is also indicated in the treatment of thyrotrophic adenoma,[4] a rare tumor of the pituitary gland which secretes TSH.

Interestingly, lanreotide also shows activity against non-endocrine tumors, and, along with other somatostatin analogues, is being studied as a possible general antitumor agent.[5][6]

Side effects

The main side effects of lanreotide treatment are mild to moderate pain at the injection site and gastrointestinal disturbances, such as diarrhea, nausea and vomiting. Isolated cases of gallstone formation have been associated with use of lanreotide, particularly over long periods of time.[1][4]

Formulations

Lanreotide is available in two formulations: a sustained release formulation (sold under the trade name Somatuline LA), which is injected intramuscularly every ten or fourteen days,[4] and an extended release formulation (UK trade name Somatuline Autogel, or Somatuline Depot in the U.S.), which is administered subcutaneously once a month.[7]

References

  1. 1.0 1.1 1.2 Template:Fr icon "Lanreotide Acetate". BIAM. March 5, 2001. Retrieved 2007-03-02.
  2. "FDA Approves New Drug to Treat Rare Disease, Acromegaly" (Press release). U.S. Food and Drug Administration. August 30 2007. Retrieved 2007-09-06. Check date values in: |date= (help)
  3. Rens-Domiano S, Reisine T (1992). "Biochemical and functional properties of somatostatin receptors". J Neurochem. 58 (6): 1987&ndash, 96. doi:10.1111/j.1471-4159.1992.tb10938.x. PMID 1315373.
  4. 4.0 4.1 4.2 "Somatuline LA". electronic Medicines Compendium. September 17, 2003. Retrieved 2007-03-02.
  5. Kvols L, Woltering E (2006). "Role of somatostatin analogs in the clinical management of non-neuroendocrine solid tumors". Anticancer Drugs. 17 (6): 601&ndash, 8. PMID 16917205.
  6. Susini C, Buscail L (2006). "Rationale for the use of somatostatin analogs as antitumor agents". Ann Oncol. 17 (12): 1733&ndash, 42. PMID 16801334.
  7. "Somatuline Autogel". electronic Medicines Compendium. April 12, 2007. Retrieved 2007-04-19.

Template:Pituitary and hypothalamic hormones and analogues

Template:WikiDoc Sources